article thumbnail

Researchers show novel device improves blood sugar control in hyperinsulinism patients whose pancreas has been removed

Scienmag

Philadelphia, September 13, 2021—Researchers at Children’s Hospital of Philadelphia (CHOP) have demonstrated that an experimental device can improve blood sugar control in patients who developed diabetes after their pancreas was removed to treat their hyperinsulinism, a genetic disease in which the pancreas produces too much insulin.

article thumbnail

Hypoxia-Inducible Factor-2 Alpha (HIF-2?) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

The Pharma Data

Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective. About Von Hippel-Lindau Disease. This is a rare genetic disease with an estimated incidence of 10,000 people in the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In a first, children with rare genetic diseases get mitochondrial transplants from their mothers

STAT News

They also metabolize cholesterol and synthesize hormones and neurotransmitters. And over the next 2 billion or so years, that bacteria evolved to be the mitochondria that power nearly every cell in the human body. These capsule-shaped organelles don’t just turn oxygen and nutrients into chemical energy.

article thumbnail

Surrogate Endpoints: How to Choose the Best One for Your Rare Disease Trial

XTalks

For the following 15 rare diseases, all prevalence (approximate), symptom, etiology and treatment information was taken from the National Organization for Rare Disorders’ (NORD) Rare Disease Database , unless a link to another source is provided. Cushing’s Disease. Acromegaly. Prevalence: 50 to 70 people per 1 million.

Trials 98
article thumbnail

Key Trends in the Life Sciences to Look Forward to in 2022

XTalks

This included Eli Lilly’s partnership with Netherlands-based RNA biotech ProQR Therapeutics this year to develop RNA editing-based therapies for rare genetic diseases, namely blindness-causing retinal conditions, based on the company’s proprietary Axiomer RNA editing platform technology. The deal is worth $1.5